Parmar, A. et al. 2021. A cost-utility analysis of apalutamide for metastatic castrationsensitive prostate cancer. Canadian Urological Association Journal. 16, 3 (Oct. 2021), E126–31. DOI:https://doi.org/10.5489/cuaj.7495.